Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nyse Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

Jun. 30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
Feb. 12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

Capitalization	63.66B 54.62B 50.89B 47.35B 87.36B 5,483B 97.54B 615B 232B 2,571B 239B 234B 9,449B	P/E ratio 2018	-8.76x	P/E ratio 2019	-11.9x
Enterprise value	80.96B 69.47B 64.72B 60.22B 111B 6,973B 124B 782B 295B 3,269B 304B 297B 12,017B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	Jun. 30	CI
Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	Feb. 12	CI
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	24-10-18	CI
Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	24-08-27	CI
Allergan Aesthetics Debuts Alle Payment Plans	24-06-27	CI
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	24-03-05	CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	23-09-18	CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	23-08-30	CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	23-05-15	CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	23-01-18	CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection	23-01-17	CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting	22-10-07	CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body	22-08-31	CI

Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	24-04-01	AQ
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	22-04-20	AQ
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	22-04-06	AQ
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	22-03-22	AQ
Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	21-12-10	AQ

Allergan plc Stock

Equities

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news: Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Other Pharmaceuticals

Financials

Company Profile

Planète Bourse : La revue de presse du mardi 20 avril 2021	21-04-20
EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...	20-05-07
La Chine repart, mais Washington veille	20-05-07
EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...	20-05-06
Trump franchit le Rubicon	20-05-06

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	55	2016-11-30
Robert Michael PSD	President	54	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	54	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	+1.34%	-2.69%	-9.09%	+139.83%	693B
JOHNSON & JOHNSON	+0.44%	+4.33%	+5.33%	-6.04%	394B
ABBVIE INC.	-1.12%	-1.66%	+10.59%	+26.54%	334B
NOVO NORDISK A/S	-2.22%	-5.55%	-53.26%	-1.90%	287B
ROCHE HOLDING AG	+0.58%	+0.66%	-7.15%	-21.43%	259B
NOVARTIS AG	-1.12%	-4.09%	-2.94%	+12.40%	223B
ASTRAZENECA PLC	-0.17%	-1.49%	-15.11%	-7.23%	215B
MERCK & CO., INC.	-1.91%	-4.08%	-35.65%	-13.41%	201B
AMGEN INC.	-1.17%	-0.17%	-10.94%	+20.88%	158B
Average	-0.46%	-1.40%	-13.14%	+16.63%	282.86B
Weighted average by Cap.	-0.40%	-1.59%	-11.07%	+35.84%

	2018	2019
Net sales	15.79B 13.55B 12.62B 11.74B 21.67B 1,360B 24.19B 152B 57.56B 637B 59.22B 57.99B 2,343B	16.09B 13.8B 12.86B 11.97B 22.08B 1,386B 24.65B 155B 58.66B 650B 60.35B 59.1B 2,388B
Net income	-5.1B -4.37B -4.07B -3.79B -6.99B -439B -7.81B -49.22B -18.58B -206B -19.12B -18.72B -756B	-5.27B -4.52B -4.21B -3.92B -7.23B -454B -8.08B -50.91B -19.22B -213B -19.77B -19.36B -782B
Net Debt	21.89B 18.78B 17.5B 16.28B 30.04B 1,885B 33.54B 211B 79.81B 884B 82.11B 80.41B 3,249B	17.3B 14.85B 13.83B 12.87B 23.75B 1,490B 26.52B 167B 63.09B 699B 64.91B 63.56B 2,568B